Editas Medicine (EDIT) EPS (Weighted Average and Diluted) (2019 - 2025)
Editas Medicine (EDIT) reported EPS (Weighted Average and Diluted) of -$0.28 for Q3 2025, up 62.67% year-over-year from -$0.17 in Q3 2024, and up 55.56% quarter-over-quarter from -$0.63 in Q2 2025.
Editas Medicine (EDIT) EPS (Weighted Average and Diluted) (2019 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 7 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.28 in Q3 2025.
- EPS (Weighted Average and Diluted) for Q3 2025 came in at -$0.28, up 62.67% year-over-year; the trailing twelve-month figure through Sep 2025 was -$2.38 (up 6.3% YoY), and the FY2024 annual result was -$2.88, down 42.57% from the prior year.
- EPS (Weighted Average and Diluted) climbed to -$0.28 in Q3 2025 per EDIT's latest filing, from -$0.63 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at -$0.21 in Q4 2023 and troughed at -$0.92 in Q1 2025.
- A 5-year average of -$0.67 and a median of -$0.74 in 2022 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2021 and 2023: EPS (Weighted Average and Diluted) plunged 575.0% in 2021, then soared 76.14% in 2023.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.61 in 2021, then tumbled by 44.26% to -$0.88 in 2022, then soared by 76.14% to -$0.21 in 2023, then plunged by 161.9% to -$0.55 in 2024, then soared by 49.09% to -$0.28 in 2025.
- Business Quant data shows EDIT's EPS (Weighted Average and Diluted) at -$0.28 in Q3 2025, -$0.63 in Q2 2025, and -$0.92 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Editas Medicine | 262.77 Mn | 262.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -0.28 |
| Jun 30, 2025 | -0.63 |
| Mar 31, 2025 | -0.92 |
| Dec 31, 2024 | -0.55 |
| Sep 30, 2024 | -0.75 |
| Jun 30, 2024 | -0.82 |
| Mar 31, 2024 | -0.76 |
| Dec 31, 2023 | -0.21 |
| Sep 30, 2023 | -0.55 |
| Jun 30, 2023 | -0.56 |
| Mar 31, 2023 | -0.71 |
| Dec 31, 2022 | -0.88 |
| Sep 30, 2022 | -0.81 |
| Jun 30, 2022 | -0.78 |
| Mar 31, 2022 | -0.74 |
| Dec 31, 2021 | -0.61 |
| Sep 30, 2021 | -0.57 |
| Jun 30, 2021 | -0.81 |
| Mar 31, 2021 | -0.86 |
| Dec 31, 2020 | -1.05 |